MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.
Mayer L, Weskamm LM, Fathi A, Kono M, Heidepriem J, Krähling V, Mellinghoff SC, Ly ML, Friedrich M, Hardtke S, Borregaard S, Hesterkamp T, Loeffler FF, Volz A, Sutter G, Becker S, Dahlke C, Addo MM.
Mayer L, et al. Among authors: sutter g.
NPJ Vaccines. 2024 Jan 26;9(1):20. doi: 10.1038/s41541-023-00801-z.
NPJ Vaccines. 2024.
PMID: 38278816
Free PMC article.